Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also kept its price target at $445 for the stock. Stifel’s analysts referenced Vertex’s presentation of povetacicept (a dual BAFF/APRIL inhibitor) open-label Phase 1/2 results at the American Society of Nephrology (ASN) on November 8. They highlighted strong efficacy for both I ...